{
    "title": "Individual feed for https://www.2minutemedicine.com/feed/",
    "link": "https://www.2minutemedicine.com/feed/",
    "description": "Individual feed output.",
    "lastBuildDate": "2026-01-16T06:09:57.108078",
    "items": [
        {
            "title": "Edaravone dexborneol improves functional independence in patients with acute ischaemic stroke following endovascular thrombectomy",
            "link": "https://www.2minutemedicine.com/edaravone-dexborneol-improves-functional-independence-in-patients-with-acute-ischaemic-stroke-following-endovascular-thrombectomy/",
            "description": "1. Compared to placebo, edaravone dexborneol improved functional independence at 90 days in patients with acute ischaemic stroke who underwent endovas...",
            "pubDate": "2026-01-16T00:00:40",
            "image_url": "https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture3.png"
        },
        {
            "title": "Yartemlea (narsoplimab-wuug) improves platelets hemolysis organ function hematopoietic stem cell transplant–associated thrombotic microangiopathy transplant patients",
            "link": "https://www.2minutemedicine.com/yartemlea-narsoplimab-wuug-improves-platelets-hemolysis-organ-function-hematopoietic-stem-cell-transplant-associated-thrombotic-microangiopathy-transplant-patients/",
            "description": "1. Yartemlea (narsoplimab-wuug) is the first on‑label complement inhibitor for hematopoietic stem cell transplant (HSCT) associated thrombotic microan...",
            "pubDate": "2026-01-15T18:48:46",
            "image_url": "https://www.2minutemedicine.com/wp-content/uploads/2014/12/Human_embryonic_stem_cells-300x150.png"
        },
        {
            "title": "FDA highlights flexible chemistry manufacturing controls expectations for cell and gene therapies",
            "link": "https://www.2minutemedicine.com/fda-highlights-flexible-chemistry-manufacturing-controls-expectations-for-cell-and-gene-therapies/",
            "description": "1. New FDA communication introduces a more flexible, risk‑based chemistry, manufacturing, and controls (CMC) framework for cell and gene therapies, in...",
            "pubDate": "2026-01-15T15:20:39",
            "image_url": "https://lead-mark.github.io/snippets/genNewsImagesTwo/Picture5.png"
        },
        {
            "title": "One in three people with cystic fibrosis may experience nephrolithiasis during their life",
            "link": "https://www.2minutemedicine.com/one-in-three-people-with-cystic-fibrosis-may-experience-nephrolithiasis-during-their-life/",
            "description": "1. Nearly one in three people with cystic fibrosis experienced nephrolithiasis during their lifetime. 2. The degree of exocrine pancreatic insufficien...",
            "pubDate": "2026-01-15T00:00:14",
            "image_url": "https://www.2minutemedicine.com/wp-content/uploads/2016/11/CC_kidneystone_hazydan_wiki_edited-300x150.png"
        },
        {
            "title": "Nuzolvence (Zoliflodacin) first oral Gonorrhea treatment shows non-inferior cure rates",
            "link": "https://www.2minutemedicine.com/nuzolvence-zoliflodacin-first-oral-gonorrhea-treatment-shows-non-inferior-cure-rates/",
            "description": "1. Nuzolvence (zoliflodacin) is the first single‑dose oral agent for uncomplicated urogenital gonorrhea, showing non‑inferior cure rates to ceftriaxon...",
            "pubDate": "2026-01-14T19:40:43",
            "image_url": "https://www.2minutemedicine.com/wp-content/uploads/2014/09/gonorrhea-e1411353243851-300x150.jpg"
        }
    ]
}